Anabolic-Androgenic Steroids

Norethandrolone is an anabolic steroid which is closely related to the steroid nandrolone in its structure. Although this steroid is essentially nandrolone modified to make oral dosing viable, it cannot be looked at as simply an oral alternative to Deca Durabolin. Norethandrolone was first developed in the 1950s. It was then developed into a prescription medication by the the pharmaceutical company Searle, which introduced it to the US prescription drug market under the brand name of Nilevar in the late 1950s.The drug was originally sold as an oral tablet, and oral solution, and an injectable solution in ampoules. The inectable form of this drug has been out of commerce for so long that few even remember that it ever existed. Nilevar was prescribed for a variety of illnesses that could be benefited by a protein sparing anabolic agent. Listed indications included preparation for and recovery from surgery, severe or prolonged illness, anorexia nervosa, severe burns and trauma, decubitus, ulcers, bone fracture healing and various forms of malnourishment in adults and children. Norethandrolone ultimately saw only limited success as a prescription anabolic agent. It did make its way to Europe and certain other markets, but not widely. Today, this drug is available on a limited basis, mainly in Australia where it remains a popular substance on the veterinary drug market.

Bolasterone is an oral anabolic steroid which is structurally related to methyltestosterone. It differs only by the addition of a methyl group, which is the reasoning for its chemical name. The addition of this methyl group makes the activity of this steroid far different than its cousin however, and makes any comparison between the two difficult. This drug was first developed in the late 1950’s. It was closely evaluated for anabolic and androgenic effect around 3 years later. The drug was developed by the pharmaceutical company UpJohn, and was sold in the United States during the 1960s under the brand name of Myagen. It was mainly prescribed for the treatment of advanced breast cancer in women, but was also investigated for use on lean tissue sparing activity. The medical use of this drug didn’t last long however, and it soon disappeared off the market not too long after it was released. By the 1980s, the drug had pretty much been forgotten by bodybuilders and athletes. Although bolasterone is no longer produced, the drug remains listed in the U.S Pharmacopeias, suggesting that it wouldn’t be impossible to see the drug available once again as a prescription medication in the U.S, however this remains very unlikely.

Miotolan is an oral anabolic derived from dihydrotestosterone. This agent is moderately anabolic, with only mild androgenic properties. This is no doubt due to the modification of the steroid’s A-ring, which allows the steroid structure to stay stable and bind receptors in muscle tissue long enough to provide an anabolic benefit. Furazabol was first developed in the 1960s. The only modern pharmaceutical preparation o f record containing furazabol, at least known to researches in the West, was miotolan from Daiichi Seiyaku Labs in Japan, which was sold in Japan mainly during the 1970’s and 80’s. The drug itself is scarcely mentioned in the Western medical literature, and consequently a great deal of myth has come to surround it around athletes. A realistic appraisal sits this drug in a very similar class to winstrol, however, with both agents being moderately strong anabolics with low androgenic activity. Aside from this, it is difficult to ascribe any drastically unique traits to this drug. Today, furazabol is very scarcely known to bodybuilders and athletes. The Miotolan brand from Japan was discontinued many years ago, and no pharmaceutical preparation containing furazabol has been known to exist since. The drug is still located on the black market, however, due to the fact that raw powder is still being produced in Asia. Currently, the actual number of products containing this drug is small, although it could easily expand if the market ever created a demand. It is unlikely that an actual prescription agent containing this substance will ever be seen again.

Metribolone is an oral steroid which is a derivative of the hormone trenbolone which has been C17 alpha alkylated so make it possible to be taken orally. This modification has created a steroid that is considerably stronger than the drug it is derived from. This drug was first developed in the 1960s and was used clinically in the 60s and 70s mainly for the treatment of advanced cases of breast cancer. Here, its exceedingly strong anabolic/androgenic action helps the drug counter the local effects of endogenous estrogens, lending it some efficacy for slowing or even regressing tumor growth. Such application didn’t last long however, as more realistic evaluations of the drug’s toxicity soon led to the end of its use in human medicine. By the 1970s, metribolone was becoming an accepted standard in non human research studies, especially those pertaining to the study of the androgen receptor activity. For this purpose the drug is very well suited. Its sheer potency and resistance to serum-binding proteins makes it an excellent in vitro receptor-binding standard to compare other agents to. These days, metribolone’s official use remains only for research purposes. However, some interest has gained in the black market and the drug is being seen in circulation now on the international scene.

Methyl 1 testosterone is an oral anabolic steroid which is derived from the hormone dihydrotestosterone. It is closest in structure to the hormone dihydroboldenone differing only by the addition of c-17 alkylation which changes the activity of this drug considerably. Methyl 1 testosterone was first developed in the 1960s. This compound was developed during some of the most active years of steroid research, a time when literally hundreds of different effective anabolic agents were being actively studied and persued by pharmaceutical companies. Although this substance showed some very favorable qualities and a desirable anabolic to androgenic ratio, like many other compounds developed during this time, Methyl 1 testosterone was never actually produced and marketed for any medical purposes. After this, the drug was pretty much forgotten about and laid dormant in the pages of medical books and research journals for around 40 years. The drug then reemerged sharply in 2003, when it was marketed as an over the counter supplement in the United States, which was possible due to the fact that it was virtually unknown during the time the 1991 anabolic steroids laws were written, and therefore wasn’t included. However, production was discontinued after the laws were reformed in 2005 to include this substance as a controlled anabolic steroid. Currently there is no prescription drug containing this compound.

Methandriol is an anabolic steroid which is a derivative of the hormone dihydrotestosterone. Methandriol Dipropionate has an added propionate ester added which makes the drug active in the body for several days instead of the short period of time that the unesterfied preparation of this substance is also available in. Methandriol was first developed in the 1930’s, making it a very old agent as far as anabolic steroids are concerned. Methandriol was developed into a medication by the pharmaceutical company Organon, which sold it in the US under the Stenedriol brand name. When Organon was marketing this item, it was available in both oral and injectable forms. Many other manufacturers soon followed producing this drug and it became a widely popular anabolic steroid during the 1950s. Methandriol was essentially the first steroid perceived to have a notable separation of anabolic and androgenic effect, which was a persistent goal of pharmaceutical developers at the time. But it was later confirmed that the dosages needed to cause any tissue growth in humans would also cause androgenic side effects due to the week anabolic nature of this substance. Soon more effective anabolic preparations became available and Organon and the rest of the companies producing this drug discontinued its production. Now it’s only found in international markets, mainly Australia where it is marketed as a veterinary medicine.

MENT, which is short for methylnortestosterone, is an anabolic steroid which is a derivative of the hormone nandrolone. This product is less commonly referred to trestolone acetate. MENT was first developed in the 1960’s, but never gained much popularity in the drug community and therefore was never made it to becoming a commercially sold drug product. Recently however, the large pharmaceutical company Schering AG made a public statement that it had reached an agreement with an outside company to research, market and develop MENT as a prescription drug. Schering has said publicly that MENT will be an easier to administer yet equally effective steroid as is testosterone products for the purposes for which it is prescribed. It is suspected that the drug will be made available in an implant preparation, in which implants will be placed inside the user and will then yield a gradual release of the hormone into the body’s system. If the drug is marketed into an implant, it will most likely be impractical to use for bodybuilding and performance enhancing purposes unless it can somehow be converted into an injectable preparation.

Clostebol acetate is an anabolic steroid that is a derivative of testosterone. Clostebol is 4-chloro-testosterone, a modification that makes this drug a low strength anabolic compound with minimal androgenic potency. Clostebol acetate was first produced in 1956 and was developed into a prescription medication in Europe where it was marketed under the name Steranabol by the company Farmitalia, and the name Turinabol by a company called Jenapharm. The original medical use for this product was to treat osteoporosis, and then later was found to be successful when used to treat conditions of anorexia and certain types of liver disease. Clostebol acetate was made in both the form of oral pills and also an injectable preparation. This drug was widely used with females and elderly patients due to the mild anabolic nature of it. Although quite favorable in effect and the comfort of use, clostebol acetate was never really successful as an anabolic and saw only limited use in a small number of markets. Eventually all manufacturers of this product ceased production of the injectable and oral forms of the compound. Although the injectable version of this product are now off the markets, clostebol acetate is still manufactured by a number of companies in the form of a dermal preparation. The most popular brand of this product is produced in Italy. The dermal preparations of this steroid are usually used in the treatment of wounds and ulcers.

Drostanolone propionate is an injectable anabolic steroid derived from dihydrostestosterone (DHT). Here, the DHT has been modified with a 2-methyl group to increase its anabolic properties, making this drug much more effective at promoting muscle growth than the non-methylated DHT. Drostanolone propionate was founded in the 1950’s. A company called Syntex developed the compound along with such other well known steroids as Anadrol and Superdrol. Around ten years later masteron drostanolone was first introduced as a prescription medication. In the US, the FDA approved drostanolone for use in postmenopausal women for the treatment of inoperable breast cancer. Eventually other prescription medications were developed which better served the same conditions that this drug was originally approved for, and slowly manufacturers began to voluntarily discontinue production of it. Now days, this drug is no longer available as a prescription drug and can only be purchased on the black market where it is still a popular compound amongst the bodybuilding and performance enhancing community.

Laurabolin is an inectable form of the anabolic steroid nandrolone. The ester attatched to nandrolone in Laurabolin s slightly larger than that used in Deca Durabolin, and thus causes a slightly slower release from the injection sight than does Deca. Because of this slow release, Laurabolin can be comfortably injected once every 1 to 2 weeks. Although it is no longer being made, Laurabolin was once highly sought after by athletes and bodybuilders due to its ability to promote slow, steady gains in lean muscle mass with minimal estrogen or androgen related side effects.